mRNA CAR-T therapy for severe lupus or autoimmune anemia
Part of Blood & lymphatic, Immune system & allergy, Skin clinical trials.
This early-stage trial tests a new mRNA-based therapy called Arnovie101 that trains your immune cells to fight lupus (SLE) or autoimmune hemolytic anemia (AIHA) that haven't improved with standard treatments. The therapy may help reduce disease activity and symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–60 years old
- Diagnosed with lupus (SLE) or autoimmune hemolytic anemia (AIHA) that hasn't responded well to at least 2–3 prior treatments
- Stable on current lupus or anemia medications for at least 8 weeks (SLE) or have tried multiple therapies (AIHA)
- Adequate kidney, liver, bone marrow, heart, and lung function
- No active infections (HIV, hepatitis B/C, tuberculosis, or recent shingles)
- No history of organ transplant, cancer in past 5 years, brain/neurological complications from lupus, or prior CAR-T therapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special immune cell therapy (CAR T cells) for people with severe lupus, Sjogren's syndrome, systemic sclerosis, and other autoimmune conditions that haven't improved with standard treatments. The therapy is designed to target and reset the immune system.
This trial tests a treatment where your own immune cells are modified to attack and destroy lupus-causing B cells. It's for people with lupus (SLE) that hasn't improved with standard treatments.
This trial tests whether a special immune cell treatment (CD19 CAR-T) can help people with certain severe autoimmune diseases that have not improved with standard therapies. It is a very early study to see if the treatment is safe and effective for conditions like lupus, systemic sclerosis, vasculitis, myositis, or Sjögren's syndrome.
This study tests a new mRNA treatment that targets CD19, a protein on some immune cells that cause autoimmune diseases. It aims to help people with severe or treatment-resistant autoimmune diseases like immune thrombocytopenia, autoimmune hemolytic anemia, lupus, or scleroderma, where the immune system attacks the body's own tissues.
This trial is testing whether a type of immune cell therapy called CAR-T cells can help people with severe autoimmune diseases that have not improved with standard treatments. It may offer a new option for conditions like lupus, Sjogren's syndrome, or vasculitis when other therapies have failed.
This trial tests an experimental therapy called IC19 CAR-T cells, which are specially modified immune cells, for people with severe lupus that hasn't gotten better with standard treatments. The goal is to see if this therapy can calm the immune system and reduce lupus symptoms.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.